FHIR IG analytics

Resources that use this resource

No resources found

Resources that this resource uses

No resources found

Narrative

Note: links and images are rebased to the (stated) source

Source1

{
  "resourceType": "Library",
  "id": "179618",
  "meta": {
    "versionId": "3",
    "lastUpdated": "2023-11-26T21:01:14.757Z",
    "profile": [
      "http://hl7.org/fhir/uv/ebm/StructureDefinition/systematic-review-included-studies"
    ]
  },
  "text": {
    "status": "extensions",
    "div": "<!-- snip (see above) -->"
  },
  "extension": [
    {
      "url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status",
      "valueCodeableConcept": {
        "coding": [
          {
            "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type",
            "code": "active",
            "display": "Active"
          }
        ]
      }
    }
  ],
  "url": "https://fevir.net/resources/Library/179618",
  "identifier": [
    {
      "type": {
        "coding": [
          {
            "system": "http://terminology.hl7.org/CodeSystem/v2-0203",
            "code": "ACSN",
            "display": "Accession ID"
          }
        ],
        "text": "FEvIR Object Identifier"
      },
      "system": "https://fevir.net/FOI",
      "value": "179618",
      "assigner": {
        "display": "Computable Publishing LLC"
      }
    },
    {
      "system": "urn:ietf:rfc:3986",
      "value": "urn:oid:2.16.840.1.113883.4.642.40.44.28.3"
    }
  ],
  "version": "1.0.0-ballot3",
  "title": "SystematicReviewIncludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer",
  "status": "active",
  "type": {
    "coding": [
      {
        "system": "http://terminology.hl7.org/CodeSystem/library-type",
        "code": "asset-collection",
        "display": "Asset Collection"
      }
    ]
  },
  "subjectReference": {
    "reference": "Group/179619",
    "type": "Group",
    "display": "SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer"
  },
  "date": "2023-11-26T18:15:27.442Z",
  "publisher": "HL7 International / Clinical Decision Support",
  "contact": [
    {
      "name": "HL7 International / Clinical Decision Support",
      "telecom": [
        {
          "system": "url",
          "value": "http://www.hl7.org/Special/committees/dss"
        }
      ]
    }
  ],
  "description": "3 included studies",
  "useContext": [
    {
      "code": {
        "system": "https://fevir.net/resources/CodeSystem/179423",
        "code": "evidence-communication",
        "display": "Evidence Communication"
      },
      "valueCodeableConcept": {
        "coding": [
          {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "SystematicReviewIncludedStudies",
            "display": "SystematicReviewIncludedStudies"
          }
        ]
      }
    }
  ],
  "jurisdiction": [
    {
      "coding": [
        {
          "system": "http://unstats.un.org/unsd/methods/m49/m49.htm",
          "code": "001",
          "display": "World"
        }
      ]
    }
  ],
  "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/",
  "author": [
    {
      "name": "Brian S. Alper"
    }
  ],
  "relatedArtifact": [
    {
      "type": "derived-from",
      "resourceReference": {
        "reference": "Citation/179613",
        "type": "Citation",
        "display": "27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis."
      }
    },
    {
      "type": "contains",
      "resourceReference": {
        "reference": "Citation/179615",
        "type": "Citation",
        "display": "23306100 Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial."
      }
    },
    {
      "type": "contains",
      "resourceReference": {
        "reference": "Citation/179617",
        "type": "Citation",
        "display": "25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the 'Docetaxel Era': Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)."
      }
    },
    {
      "type": "contains",
      "resourceReference": {
        "reference": "Citation/179616",
        "type": "Citation",
        "display": "26244877 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer."
      }
    }
  ]
}